Petrelintide: The Amylin Drug Betting on Tolerability, Not Percentages
Zealand Pharma's stock fell after this drug hit its primary endpoint. That reaction tells you something real about how the obesity market values weight loss - and it may turn out to be wrong.
Last updated: August 3, 2026
Petrelintide Is Not Approved or Available
Petrelintide is an investigational drug in clinical development. It is not FDA-approved, not available by prescription anywhere, and Phase 3 trials were only planned to begin in the second half of 2026. Anything sold online claiming to be petrelintide is not a legitimate product - see the warning at the end of this article.
Quick Answer
Petrelintide is a long-acting amylin analog developed by Zealand Pharma in partnership with Roche. Unlike almost everything else in the pipeline, it is not a GLP-1 drug at all - it works through a different hormone entirely.
In the ZUPREME-1 Phase 2 trial, reported by Roche on 5 March 2026, petrelintide met its primary endpoint with up to 10.7% mean body weight reduction at week 42, versus 1.7% on placebo - and, critically, with what the companies described as "placebo-like" tolerability. Earlier 16-week data had shown reductions of 4.8%, 8.6% and 8.3% across dose levels.
The market did not love it. Zealand's stock fell sharply after the readout, because 10.7% looks unimpressive next to tirzepatide's 20-22%. That reaction judges petrelintide on the wrong axis - which is the argument this article makes.
What Amylin Is and Why It Matters
Nearly every drug covered on this site works on GLP-1, sometimes with GIP or glucagon added. Petrelintide works on something else: amylin.
Amylin is a hormone co-secreted with insulin by pancreatic beta cells. Its jobs include slowing gastric emptying, suppressing inappropriate glucagon release after meals, and - most relevantly - signaling satiety through a different brain pathway than GLP-1 uses.
That last point is the whole thesis. If you can reduce food intake through a separate route, you may be able to achieve meaningful weight loss without the nausea, vomiting and diarrhea that cause a substantial share of people to abandon GLP-1 therapy.
Amylin is not a new idea - pramlintide (Symlin) has existed for years, but required multiple daily injections and never gained traction for weight management. Petrelintide is a long-acting, once-weekly analog, which is what makes the approach practical. It is also why Novo Nordisk pairs cagrilintide, another amylin analog, with semaglutide in CagriSema.
ZUPREME-1: The Numbers
| Study / Timepoint | Result |
|---|---|
| ZUPREME-1, week 42 (primary endpoint) | Up to 10.7% mean weight reduction vs 1.7% placebo |
| Week 28 | Statistically significant reductions across all five treatment arms |
| Earlier study, 16 weekly doses | 4.8%, 8.6% and 8.3% at up to 2.4 mg, 4.8 mg and 9.0 mg |
| Tolerability | Described as "placebo-like"; low incidence of GI adverse events |
Two details in that table deserve attention beyond the headline. All five treatment arms hit significance at week 28, which is a cleaner result than a single winning dose. And the earlier dose-ranging data is notable for what it does not show - 8.6% at 4.8 mg versus 8.3% at 9.0 mg means the curve flattened, so pushing the dose higher did not buy more weight loss.
A separate analysis presented at a diabetes conference noted that women appeared to respond better to petrelintide, with retained effect - a sex difference worth tracking through Phase 3.
Why "Placebo-Like Tolerability" Is the Story
Weight loss percentages from clinical trials measure what happens to people who stay on the drug. Real-world outcomes depend on something the percentage never captures: whether people keep taking it.
GLP-1 discontinuation is a substantial and well-documented problem. Nausea, vomiting, diarrhea and constipation drive a meaningful share of people off therapy - often during dose escalation, before they ever reach the doses that produce trial-level results. A drug that delivers 22% on paper delivers 0% to someone who quit at week six.
The petrelintide bet: a tolerable 10.7% that people actually stay on may beat a punishing 20% they abandon. Fiercebiotech framed the tolerability result as setting a new bar, and that is the right frame. If the profile holds through Phase 3, petrelintide becomes the obvious option for the large group of people who cannot tolerate GLP-1s - a group nobody currently serves well.
The caveat is real, though: "placebo-like tolerability" is a company characterization from a press release, not yet a peer-reviewed safety database. Phase 2 trials are smaller and shorter than Phase 3, and tolerability claims have a habit of softening at scale. This is a promising signal, not a settled fact.
Why the Stock Fell on Good News
Zealand's share price dropped sharply after the March 2026 readout, despite the trial meeting its primary endpoint. Worth understanding, because it shapes coverage you will read elsewhere.
Investors price obesity drugs largely on peak weight loss, because that is the number that wins prescriptions in a market where tirzepatide already delivers 20-22%. Against that benchmark, 10.7% reads as a miss regardless of how well tolerated it was.
What this means for you as a patient rather than an investor: a disappointing stock reaction is not a clinical verdict. The question that matters to you is not "does this beat tirzepatide on percentage" but "is there a version of this I could actually stay on." Those are different questions, and the market only prices the first one.
It is also worth noting that Roche - which partnered on the drug and has no shortage of options - continued advancing it to Phase 3 after seeing the full data.
Petrelintide vs the Rest of the Pipeline
| Drug | Mechanism | Weight Loss | Selling Point |
|---|---|---|---|
| Petrelintide | Amylin analog (no GLP-1) | 10.7% at 42 weeks | Tolerability |
| Retatrutide | GLP-1 + GIP + glucagon | 28.3% at 80 weeks | Maximum efficacy |
| CagriSema | GLP-1 + amylin | ~20%+ | Combination approach |
| Amycretin | GLP-1 + amylin, one molecule | Up to ~22% reported | Unimolecular design |
| Survodutide | GLP-1 + glucagon | 16.6% at 76 weeks | Liver benefit |
Petrelintide is the outlier - the only one competing on something other than the percentage. Note that CagriSema and amycretin also use amylin, but combined with GLP-1. Petrelintide is testing whether amylin alone is enough for a distinct group of patients.
Zealand has said petrelintide is also being explored in combination, which would be the natural next step: amylin as the tolerable backbone, with something added for people who need more.
Timeline and Availability
Zealand Pharma stated that petrelintide would advance into Phase 3 trials for chronic weight management with a planned initiation in the second half of 2026.
Working forward from that: Phase 3 obesity programs typically run 68-80 weeks, followed by data analysis, an FDA submission, and a review period. A realistic earliest approval is 2029-2030, and that assumes everything goes well. This is a long way out.
Do not buy anything sold as petrelintide. There is no legitimate source. Any website offering it is selling either a research chemical of unverified identity and purity, or nothing at all. Peptides marketed this way have been found to contain wrong compounds, wrong doses, and bacterial contamination.
The same applies to retatrutide, cagrilintide, and every other unapproved compound with a gray market. Investigational status means the safety profile is not established - that is the entire point of the trials still running.
If GLP-1 side effects are what has you reading about petrelintide, the more useful move is addressing them now: slower titration, dose adjustment, and the practical strategies in our guides to managing GLP-1 nausea and GLP-1 constipation. Many people who quit could have stayed on with better management.
Frequently Asked Questions
What is petrelintide?
A long-acting, once-weekly amylin analog developed by Zealand Pharma in partnership with Roche. It is not a GLP-1 drug - amylin is a separate hormone, co-secreted with insulin, that signals satiety through a different brain pathway. The goal is meaningful weight loss without the gastrointestinal side effects that drive people off GLP-1 therapy.
How much weight loss does petrelintide produce?
In the ZUPREME-1 Phase 2 trial reported in March 2026, up to 10.7% mean body weight reduction at week 42 versus 1.7% on placebo, with all five treatment arms reaching statistical significance by week 28. Earlier dose-ranging data over 16 weekly doses showed 4.8%, 8.6% and 8.3% at up to 2.4 mg, 4.8 mg and 9.0 mg respectively.
Is petrelintide a peptide?
Yes. It is a peptide-based analog of human amylin, engineered for a long half-life so it can be given once weekly. That is the practical advance over pramlintide, an earlier amylin drug that required multiple daily injections and never gained traction for weight management.
Why did Zealand's stock fall if the trial succeeded?
Investors price obesity drugs mainly on peak weight loss, and 10.7% reads as a miss against tirzepatide's 20-22%. That is a commercial judgment, not a clinical one. The patient-relevant question is whether a tolerable drug you stay on beats a punishing one you quit - which the market reaction does not price at all. Roche advanced it to Phase 3 after seeing the full data.
When will petrelintide be available?
Not for years. Phase 3 was planned to begin in the second half of 2026. Obesity Phase 3 programs typically run 68-80 weeks, then require analysis, FDA submission, and review. A realistic earliest approval is 2029-2030, assuming everything goes well.
How is petrelintide different from CagriSema?
Both involve amylin, but CagriSema pairs an amylin analog (cagrilintide) with semaglutide, a GLP-1. Petrelintide is amylin alone. That makes it the cleaner test of whether the amylin pathway is sufficient on its own - and it is why petrelintide's side effect profile can be so much milder, since there is no GLP-1 component driving the usual nausea.
Can I buy petrelintide online?
No, and you should not try. Petrelintide is investigational with no legitimate commercial source anywhere. Anything sold under that name is a research chemical of unverified identity, dose and purity - a category where testing has repeatedly found wrong compounds and bacterial contamination. Its safety profile in humans is precisely what the ongoing trials are still establishing.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Petrelintide is an investigational drug that is not FDA-approved and is not available by prescription. Nothing here should be read as encouragement to obtain it from any source. Clinical trial figures are drawn from company announcements and conference presentations, represent group averages, and do not predict individual results; Phase 2 results frequently change at Phase 3 scale. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. HealthyPound may receive compensation from affiliate partners mentioned in this article. See our affiliate disclosure and full medical disclaimer.